Check for updates

OPEN ACCESS

APPROVED BY Olivier Feron, Université catholique de Louvain, Belgium

*CORRESPONDENCE Frontiers Editorial Office, research.integrity@frontiersin.org

RECEIVED 04 December 2023 ACCEPTED 04 December 2023 PUBLISHED 07 December 2023

CITATION

Frontiers Editorial Office (2023), Retraction: Berberine maintains the neutrophil N1 phenotype to reverse cancer cell resistance to doxorubicin. *Front. Pharmacol.* 14:1349235. doi: 10.3389/fphar.2023.1349235

COPYRIGHT

© 2023 Frontiers Editorial Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Retraction: Berberine maintains the neutrophil N1 phenotype to reverse cancer cell resistance to doxorubicin

Frontiers Editorial Office*

A Retraction of the Original Research Article

Berberine maintains the neutrophil N1 phenotype to reverse cancer cell resistance to doxorubicin

by Zhang S, Zhou L, Zhang M, Wang Y, Wang M, Du J, Gu W, Kui F, Li J, Geng S and Du G (2020). Front. Pharmacol. 10:1658. doi: 10.3389/fphar.2019.01658

The journal retracts the 29 January 2020 article cited above.

Following publication, concerns were raised regarding the integrity of the images in the published figures. The authors failed to provide a satisfactory explanation during the investigation, which was conducted in accordance with Frontiers' policies. As a result, the data and conclusions of the article have been deemed unreliable and the article has been retracted.

This retraction was approved by the Chief Editors of Frontiers in Pharmacology and the Chief Executive Editor of Frontiers. The authors agree to this retraction.